



CRC: Key Journal Articles and Abstracts

[Bennouna J, Sastre J, Arnold D, et al; ML18147 Study Investigators. Continuation of bevacizumab after first progression in metastatic colorectal cancer \(ML18147\): a randomised phase 3 trial. *Lancet Oncol.* 2013;14\(1\):29-37.](#)

[Bettington M, Walker N, Clouston A, Brown I, Leggett B, Whitehall V. The serrated pathway to colorectal carcinoma: current concepts and challenges. *Histopathology.* 2013;62\(3\):367-386.](#)

[Boeckx N, Koukakis R, Op de Beeck K, et al. Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies. *Ann Oncol.* 2017;28\(8\):1862-1868.](#)

[Brulé SY, Jonker DJ, Karapetis CS, et al. Location of colon cancer \(right-sided versus left-sided\) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. *Eur J Cancer.* 2015;51\(11\):1405-1414.](#)

[Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. *Science.* 2017;357\(6349\):409-413.](#)

[Lenz HJ, Lonardi S, Zagonel V, et al. Nivolumab \(NIVO\) + low-dose ipilimumab \(IPI\) as first-line \(1L\) therapy in microsatellite instability-high/DNA mismatch repair deficient \(MSI-H/dMMR\) metastatic colorectal cancer \(mCRC\): clinical update. *J Clin Oncol.* 2019;37\(15 suppl\):Abstract 3521.](#)

[Overman MJ, Lonardi S, Wong KYM, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. *J Clin Oncol.* 2018;36\(8\):773-779.](#)

[Tabernero J, Yoshino T, Cohn AL, et al; RAISE Study Investigators. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine \(RAISE\): a randomised, double-blind, multicentre, phase 3 study. *Lancet Oncol.* 2015;16\(5\):499-508.](#)

[Tejpar S, Stintzing S, Ciardiello F, et al. Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials. *JAMA Oncol.* 2017;3\(2\):194-201.](#)

[Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. *J Clin Oncol.* 2012;30\(28\):3499-3506.](#)

[Venook AP, Niedzwiecki D, Innocenti F, et al. Impact of primary \(1^o\) tumor location on overall survival \(OS\) and progression-free survival \(PFS\) in patients \(pts\) with metastatic colorectal cancer \(mCRC\): analysis of CALGB/SWOG 80405 \(Alliance\). *J Clin Oncol.* 2016;34\(15 suppl\):Abstract 3504.](#)